SCHEMBL29324264

SCHEMBL29324264

CNc1nc(N)nc2c1ncn2[C@@H](C)O[C@H](CO[PH](=O)N[C@@H](C)C(=O)OC(C)C)C(C)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 9/20 0.38
ADORA1 P30542 9/20 0.38
ADORA2B P29275 7/20 0.38
CDK2 P24941 3/20 0.37
CCNA2 P20248 2/20 0.37
CCNA1 P78396 2/20 0.37
CDK1 P06493 2/20 0.37
PRKACA P17612 1/20 0.37
PRKACG P22612 1/20 0.37
PRKACB P22694 1/20 0.37
MAPK3 P27361 1/20 0.37
MAPK1 P28482 1/20 0.37
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
HDAC8 Q9BY41 1/20 0.36
ADORA2A P29274 3/20 0.32
CDC20 Q12834 1/20 0.32
CCNT1 O60563 1/20 0.31
CSNK1A1 P48729 1/20 0.31
CDK9 P50750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23761053 1.00 ADORA3 (0.38) ADORA3ADORA1ADORA2BCDK2CCNA2
SCHEMBL23094419 0.91 ADORA3 (0.36) ADORA3ADORA1ADORA2BCDK2CCNA2
SCHEMBL21101445 0.91 ADORA3 (0.36) ADORA3ADORA1ADORA2BCDK2CCNA2
SCHEMBL19644850 0.86 ADORA3 (0.38) ADORA3ADORA1ADORA2BCDK2CCNA2
SCHEMBL19833093 0.86 ADORA3 (0.38) ADORA3ADORA1ADORA2BCDK2CCNA2
SCHEMBL21101708 0.83 ADORA3 (0.34) ADORA3ADORA1ADORA2BCDK2CCNA2
SCHEMBL21101807 0.82 CDK1 (0.38) CDK2CCNA2CCNA1CDK1PRKACA
SCHEMBL22224971 0.80 ADORA3 (0.36) ADORA3ADORA1ADORA2BCDK2CCNA2
SCHEMBL22224583 0.80 ADORA3 (0.36) ADORA3ADORA1ADORA2BCDK2CCNA2
SCHEMBL20272115 0.80 ADORA3 (0.36) ADORA3ADORA1ADORA2BCDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238323-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES EMORY UNIVERSITY 2024-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240238323-A1 MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES MTAP, PNP, SARS1 ADORA3 71/4885ADORA1 69/4885ADORA2B 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.